Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk

Expert Opin Biol Ther. 2022 Apr;22(4):441-443. doi: 10.1080/14712598.2022.2028772. Epub 2022 Jan 24.

Authors

Ashish Sharma¹, Nilesh Kumar^{1

2}, Nikulaa Parachuri^{1

3}, Jean-Yves Sahyoun⁴, Baruch D Kuppermann⁵, Francesco Bandello⁶

Affiliations

¹ Lotus Eye Hospital and Institute, Coimbatore, India.
² Madhavi Netralaya, Ara, India.
³ Department of Vitreoretina, Sankara Eye Hospital, Coimbatore, India.
⁴ Department of Ophthalmology, Universite de Montreal, Quebec, Canada.
⁵ Gavin Herbert Eye Institute, University of California, Irvine, CA, USA.
⁶ Scientific Institute San Raffaele, University Vita-Salute, Milano, Italy.

PMID: 35020532
DOI: 10.1080/14712598.2022.2028772

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Humans
Intravitreal Injections

Substances

Antibodies, Monoclonal, Humanized
brolucizumab